Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1 Meeting Abstract
| Authors: | Friedman, C. F.; Sullivan, R. J.; Tschernia, N.; Sonpavde, G. P.; Herrera, M.; He, K.; Bilusic, M.; Garralda, E.; Hernando-Calvo, A. H.; Silk, A. W.; Roulleaux-Dugage, M.; Italiano, A.; Pedregal, M.; Saif, M. W.; Chin, K.; Su, Z.; Liu, K.; Siu, L. L.; Gulley, J. L.; Marabelle, A. |
| Abstract Title: | Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1 |
| Meeting Title: | Journal of Clinical Oncology |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 16_SUPPL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-01 |
| Start Page: | TPS2687 |
| End Page: | TPS2687 |
| Language: | English |
| ACCESSION: | WOS:001534392400001 |
| DOI: | 10.1200/JCO.2025.43.16_suppl.TPS2687 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- 16_SUPPL -- TPS2687 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work